Good science can’t be rushed, even when the lives of patients hang in the balance. But regulatory science, and its relationship to a drug’s commercial success or failure, can inadvertently block access to individual patients in their hour of need.
Posted in Biotech, FDA, Legal, Market Access, Regulatory, Safety, healthcare | Also tagged Abigail Alliance, breakthrough therapies, Breast cancer, Cancer, Expanded Access Programs, FDA, FDA safety and innovation act, HHS, Market Access, patient advocates, PDUFA V, policy
PharmExec Blog
Follow Us
RSS
Bookstore
Patients on the Picket Line